Astrocyte inhibition and PV interneuron activation: key mechanisms in electroacupuncture's effect on pain-anxiety comorbidity.

Chronic pain and anxiety often occur together, making both conditions harder to treat. Researchers have now discovered how electroacupuncture—a form of acupuncture using mild electrical stimulation—may help address both problems simultaneously. In this mouse study, scientists induced inflammatory pain in one paw and observed that the mice also developed anxiety-like behaviors. They then administered electroacupuncture daily for five days and found it significantly reduced both pain sensitivity and anxiety symptoms. The research team identified specific mechanisms in the brain's anterior cingulate cortex, a region involved in processing both pain and emotions. They discovered that electroacupuncture works by inhibiting overactive astrocytes (supporting brain cells) while activating special neurons called parvalbumin interneurons. These two actions work together through adenosine A1 receptors to restore normal brain function. When researchers artificially activated astrocytes, they reversed electroacupuncture's beneficial effects, confirming this pathway's importance. Conversely, when they mimicked electroacupuncture's cellular effects using advanced techniques, they achieved similar pain and anxiety relief without the actual treatment. This study provides compelling biological evidence for why electroacupuncture may be effective for patients suffering from both chronic pain and anxiety—two conditions that frequently co-occur and complicate each other. While this research was conducted in mice, it offers important insights into potential mechanisms that could translate to human treatment. If you're considering electroacupuncture for chronic pain with anxiety, consult a licensed acupuncturist with training in electroacupuncture techniques.

This preclinical study investigated electroacupuncture's effects on pain-anxiety comorbidity using a Complete Freund's adjuvant (CFA) inflammatory pain model in mice. EA was administered once daily on days 12-17 post-CFA injection. Multiple behavioral assessments (von Frey, open field, elevated plus maze, novelty-suppressed feeding) confirmed EA significantly alleviated both pain hypersensitivity and anxiety-like behaviors. Using chemogenetics, rAAV viral vectors, immunofluorescence, patch-clamp recordings, and in vivo fiber calcium imaging, researchers demonstrated EA activated parvalbumin (PV) interneurons while inhibiting astrocyte activation in the anterior cingulate cortex (ACC). Chemogenetic manipulation confirmed PV interneuron activation and astrocyte inhibition independently reproduced EA's therapeutic effects, while chemogenetic astrocyte activation reversed EA benefits. Mechanistically, adenosine A1 receptors mediate the astrocyte-PV interneuron interaction underlying EA's effects. EPCPX (A1R antagonist) blocked EA analgesia. Clinical significance: This research provides robust neurobiological evidence that EA modulates specific ACC circuits to address pain-anxiety comorbidity, supporting its use for patients with concurrent chronic pain and anxiety disorders.